top_lumigan
Logo
menutop
menubottom
find out more
   Home References       Newsroom
toplinks  
Home > Efficacy > Beta Blockers  
toolandresources
 
 

vs Beta-Blockers

LUMIGAN proven to offer superior IOP-lowering efficacy to timolol
Replacing timolol with LUMIGAN in a real-world trial results in lower mean IOP
LUMIGAN efficacy maintained through 2 years
LUMIGAN achieves additional mean IOP reduction when replacing beta-blockers

LUMIGAN proven to offer superior IOP-lowering efficacy to timolol

Mean IOP reduction at 10 AM 7

Average of 2.6 mm Hg greater reduction

Data were pooled from two 12-month, pivotal, randomized, parallel-group, double-masked, active-controlled, comparison clinical trials of 715 patients with elevated IOP (mean baseline of 26 mm Hg) following a washout period of their previous medications. Scheduled visits were at prestudy, baseline (day 0), weeks 2 and 6, and months 3, 6, and 12.

Back to top

Replacing timolol with LUMIGAN in a real-world trial results in lower mean IOP

Effects of LUMIGAN replacement of beta-blocker therapy on mean IOP 8

Replacement yields 20% additional reduction

Study was an open-label, noncomparative, surveillance trial involving 6767 patients from over 1400 clinical sites with over 1400 physicians. Data presented represented a subgroup of 587 patients who were on beta-blocker monotherapy prior to use of LUMIGAN ophthalmic solution.

Back to top

LUMIGAN efficacy maintained through 2 years

Mean IOP through 2 years, 10 AM 3

Over 2.4 mm Hg greater reduction

Data were from a 12-month pivotal extension of a multicenter, randomized, double-masked, 1-year, clinical trial. Patients were treated with bimatoprost 0.03% QD, bimatoprost 0.03% BID, or timolol 0.5% BID. Study visits took place at months 15, 18, 21, and 24. IOP was measured at 8 AM and 10 AM.

Back to top

LUMIGAN achieves additional mean IOP reduction when replacing beta-blockers

Additional mean IOP reduction at week 12 after replacing timolol with LUMIGAN 13

4.2 mm Hg additional reduction†

Data were from an open-label, 12-week evaluation of LUMIGAN in 55 patients with glaucoma or ocular hypertension who were insufficiently responsive to topical beta-blockers. Treated baseline was 20.9 mm Hg prior to LUMIGAN replacement. IOP measurements were taken at weeks 6 through 12.† Results at week 12 based on 46 patients who completed the study.

Back to top


  about_lumigan
   
  glaucoma_animation
   
  How Does Lumigan
   
   
   

LUMIGAN (bimatoprost ophthalmic solution) 0.03% is for the treatment of high eye pressure, also called intraocular pressure (IOP), in people with open-angle glaucoma or ocular hypertension.

Important Safety Information
LUMIGAN (bimatoprost ophthalmic solution) 0.03% has been reported to cause darkening (pigmentation) of eye color, eyelid skin and eyelashes, as well as increased growth of eyelashes. Pigmentation changes can increase as long as LUMIGAN is used. After stopping LUMIGAN, darkening of eye color is likely to be permanent while darkening of the eyelid skin and eyelash changes may be reversible. The effects of increased darkening beyond 5 years are not known.

The most common side effects are eye redness,  growth of eyelashes,  and itchy eyes.


 
Privacy Policy    |   Terms of Use      
 
bginner
bottom_lumigan